KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for CRISPR Therapeutics AG (CRSP) over the last 6 years, with Q4 2025 value amounting to $89.9 million.

  • CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) rose 659.8% to $89.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $89.9 million, marking a year-over-year increase of 659.8%. This contributed to the annual value of $89.9 million for FY2025, which is 659.8% up from last year.
  • As of Q4 2025, CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) stood at $89.9 million, which was up 659.8% from $91.3 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) registered a high of $91.3 million during Q3 2025, and its lowest value of $75.0 million during Q1 2021.
  • In the last 5 years, CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) had a median value of $79.4 million in 2023 and averaged $81.9 million.
  • In the last 5 years, CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) surged by 2326.71% in 2021 and then skyrocketed by 178.49% in 2023.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) stood at $75.0 million in 2021, then rose by 3.65% to $77.7 million in 2022, then grew by 1.9% to $79.2 million in 2023, then rose by 6.49% to $84.4 million in 2024, then rose by 6.6% to $89.9 million in 2025.
  • Its last three reported values are $89.9 million in Q4 2025, $91.3 million for Q3 2025, and $87.1 million during Q2 2025.